Usage of Glucagon-Like Peptide-1 for Obesity in Children; Updated Review of Clinicaltrials.gov

References

• Bays HE, Bindlish S, Clayton TL. Obesity, diabetes mellitus, and cardiometabolic risk: an Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2023. Pillars. 2023;5:100056. doi:10.1016/J.OBPILL.2023.100056
   PubMedGoogle Scholar
• Xu S, Xue Y. Pediatric obesity: causes, symptoms, prevention and treatment (review). Exp Ther Med. 2016;11:15–20. doi:10.3892/ETM.2015.2853/HTML
   PubMed Web of Science ®Google Scholar
• Chung ST, Onuzuruike AU, Magge SN. Cardiometabolic risk in obese children. Ann N Y Acad Sci. 2018;1411:166–183. doi:10.1111/NYAS.13602
   PubMed Web of Science ®Google Scholar
• Strauss RS. Childhood obesity and self-esteem. Pediatrics. 2000;105:e15–e15. doi:10.1542/PEDS.105.1.E15
   PubMed Web of Science ®Google Scholar
• Wardle J, Cooke L. The impact obesity on psychological well-being. Best Pract Res Clin Endocrinol Metab. 2005;19:421–440. doi:10.1016/J.BEEM.2005.04.006
   PubMed Web of Science ®Google Scholar
• Russell-Mayhew S, McVey G, Bardick A, Ireland A. Mental health, wellness, and childhood overweight/obesity. J Obes. 2012;2012:1–9. doi:10.1155/2012/281801
   Google Scholar
• Lumeng JC, Gannon K, Cabral HJ, Frank DA, Zuckerman B. Association between clinically meaningful behavior problems and overweight in children. Pediatrics. 2003;112:1138–1145. doi:10.1542/PEDS.112.5.1138
   PubMed Web of Science ®Google Scholar
• Stice E, Presnell K, Shaw H, Rhode P. Psychological and behavioral risk factors for obesity onset in adolescent girls: a prospective study. J Consult Clin Psychol. 2005;73:195–202. doi:10.1037/0022-006X.73.2.195
   PubMed Web of Science ®Google Scholar
• Jezewska-Zychowicz M, Gębski J, Plichta M, Guzek D, Kosicka-Gębska M. Diet-related factors, physical activity, and weight status in Polish adults. Nutrients. 2019;12:11. doi:10.3390/NU11102532
   PubMedGoogle Scholar
• Mushtaq MU, Gull S, Mushtaq K, Shahid U, Shad MA, Akram J. Dietary behaviors, physical activity and sedentary lifestyle associated with overweight and obesity, and their socio-demographic correlates, among Pakistani primary school children. Int J Behav Nutr Phys Act. 2011;8:8. doi:10.1186/1479-5868-8-130
   PubMed Web of Science ®Google Scholar
• Hartung D, Stadeler M, Grieshaber R, Keller S, Jahreis G. Work and diet-related risk factors of cardiovascular diseases: comparison of two occupational groups. J Occup Med Toxicol. 2010;5:1–8. doi:10.1186/1745-6673-5-4/TABLES/2
   PubMed Web of Science ®Google Scholar
• Costa CS, Del-Ponte B, Assunção MCF, Santos IS. Consumption of ultra-processed foods and body fat during childhood and adolescence: a systematic review. Public Health Nutr. 2018;21:148–159. doi:10.1017/S1368980017001331
   PubMed Web of Science ®Google Scholar
• Harb AA, Shechter A, Koch PA, St-Onge MP. Ultra-processed foods and the development of obesity in adults. Eur J Clin Nutr. 2022;2022:1–9. doi:10.1038/s41430-022-01225-z
   Google Scholar
• Collins L, Costello RA. Glucagon-Like Peptide-1 Receptor Agonists. StatPearls; 2022.
   Google Scholar
• Alorfi NM, Algarni AS. Clinical impact of semaglutide, a glucagon-like peptide-1 receptor agonist, on obesity management: a review. Clin Pharmacol. 2022;14:61–67. doi:10.2147/CPAA.S374741
   PubMed Web of Science ®Google Scholar
• Isaacs D, Prasad-Reddy L, Srivastava SB. Role of glucagon-like peptide 1 receptor agonists in management of obesity. Am J Heal Pharm. 2016;73:1493–1507. doi:10.2146/AJHP150990
   PubMed Web of Science ®Google Scholar
• Janez A, Muzurovic E, Stoian AP, et al. Translating results from the cardiovascular outcomes trials with glucagon-like peptide-1 receptor agonists into clinical practice: recommendations from a Eastern and Southern Europe diabetes expert group. Int J Cardiol. 2022;365:8–18. doi:10.1016/J.IJCARD.2022.07.017
   PubMed Web of Science ®Google Scholar
• Van Can J, Sloth B, Jensen CB, Flint A, Blaak EE, Saris WHM. Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults. Int J Obes. 2013;38:784–793. doi:10.1038/ijo.2013.162
   Web of Science ®Google Scholar
• Krieger JP. Intestinal glucagon-like peptide-1 effects on food intake: physiological relevance and emerging mechanisms. Peptides. 2020;131:170342. doi:10.1016/J.PEPTIDES.2020.170342
   PubMed Web of Science ®Google Scholar
• Armstrong MJ, Hull D, Guo K, et al. Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis. J Hepatol. 2016;64:399–408. doi:10.1016/J.JHEP.2015.08.038
   PubMed Web of Science ®Google Scholar
• González-García I, Milbank E, Diéguez C, López M, Contreras C. Glucagon, GLP-1 and Thermogenesis. Int J Mol Sci. 2019;20:3445. doi:10.3390/IJMS20143445
   PubMed Web of Science ®Google Scholar
• Jiang Y, Wang Z, Ma B, et al. GLP-1 improves adipocyte insulin sensitivity following induction of endoplasmic reticulum stress. Front Pharmacol. 2018;9:1168. doi:10.3389/FPHAR.2018.01168/BIBTEX
   PubMed Web of Science ®Google Scholar
• Zhang F, Chen Z, Wu D, et al. Recombinant human GLP-1 beinaglutide regulates lipid metabolism of adipose tissues in diet-induced obese mice. IScience. 2021;10:24. doi:10.1016/J.ISCI.2021.103382
   Google Scholar
• World Health Organization. Obesity and overweight; 2022. Available from: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight. Accessed March 4, 2023.
   Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi:10.1136/bmj.n71
   PubMed Web of Science ®Google Scholar
• Bridges A, Bistas KG, Jacobs TF. Exenatide. In: StatPearls. StatPearls Publishing; 2021.
   Google Scholar
• Latif W, Lambrinos KJ, Rodriguez R. Compare and Contrast the Glucagon-Like Peptide-1 Receptor Agonists (GLP1RAs). StatPearls; 2022.
   Google Scholar
• Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018;27:740–756. doi:10.1016/J.CMET.2018.03.001
   PubMed Web of Science ®Google Scholar
• Andreozzi F, Raciti GA, Nigro C, et al. The GLP-1 receptor agonists exenatide and liraglutide activate Glucose transport by an AMPK-dependent mechanism. J Transl Med. 2016;14:1–13. doi:10.1186/S12967-016-0985-7/FIGURES/8
   PubMed Web of Science ®Google Scholar
• Filippatos TD, Panagiotopoulou TV, Elisaf MS. Adverse effects of GLP-1 receptor agonists. Rev Diabet Stud. 2014;11:202. doi:10.1900/RDS.2014.11.202
   PubMedGoogle Scholar
• Consoli A, Formoso G. Potential side effects to GLP-1 agonists: understanding their safety and tolerability. Expert Opin Drug Saf. 2015;14:207–218. doi:10.1517/14740338.2015.987122
   PubMed Web of Science ®Google Scholar
• Thakur U, Bhansali A, Gupta R, Rastogi A. Liraglutide augments weight loss after laparoscopic sleeve gastrectomy: a randomised, double-blind, placebo-control study. Obes Surg. 2021;31:84–92. doi:10.1007/s11695-020-04850-4
   PubMed Web of Science ®Google Scholar
• Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2012;8:728–742. doi:10.1038/nrendo.2012.140
   PubMed Web of Science ®Google Scholar
• Gentilella R, Bianchi C, Rossi A, Rotella CM. Exenatide: a review from pharmacology to clinical practice. Diabet Obes Metab. 2009;11:544–556. doi:10.1111/J.1463-1326.2008.01018.X
   PubMed Web of Science ®Google Scholar
• Davies MJ, Donnelly R, Barnett AH, Jones S, Nicolay C, Kilcoyne A. Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the helping evaluate exenatide in patients with diabetes compared with long-acting insulin (HEELA) study. Diabet Obes Metab. 2009;11:1153–1162. doi:10.1111/J.1463-1326.2009.01154.X
   PubMed Web of Science ®Google Scholar
• Singh G, Krauthamer M, Bjalme-Evans M. Wegovy (semaglutide): a new weight loss drug for chronic weight management. J Investig Med. 2022;70:5–13. doi:10.1136/jim-2021-001952
   PubMed Web of Science ®Google Scholar
• Villela R, Correa R. Semaglutide 2.4 mg: the latest GLP-1RA approved for obesity. J Investig Med. 2022;70:3–4. doi:10.1136/JIM-2021-002227
   PubMed Web of Science ®Google Scholar
• Sharma A, Parachuri N, Kumar N, et al. Semaglutide and the risk of diabetic retinopathy—current perspective. Eye. 2021;36(36):10–11. doi:10.1038/s41433-021-01741-5
   PubMedGoogle Scholar
• Jensen L, Helleberg H, Roffel A, et al. Absorption, metabolism and excretion of the GLP-1 analogue semaglutide in humans and nonclinical species. Eur J Pharm Sci. 2017;104:31–41. doi:10.1016/J.EJPS.2017.03.020
   PubMed Web of Science ®Google Scholar
• Kim HS, Jung CH. Oral semaglutide, the first ingestible glucagon-like peptide-1 receptor agonist: could it be a magic bullet for type 2 diabetes? Int J Mol Sci. 2021;22:9936. doi:10.3390/IJMS22189936
   PubMed Web of Science ®Google Scholar
• Mahapatra MK, Karuppasamy M, Sahoo BM. Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes. Rev Endocr Metab Disord. 2022;23:521–539. doi:10.1007/S11154-021-09699-1/TABLES/5
   PubMed Web of Science ®Google Scholar
• Dahl K, Brooks A, Almazedi F, Hoff ST, Boschini C, Bækdal TA. Oral semaglutide improves postprandial glucose and lipid metabolism, and delays gastric emptying, in subjects with type 2 diabetes. Diabet Obes Metab. 2021;23:1594–1603. doi:10.1111/DOM.14373
   PubMed Web of Science ®Google Scholar
• Phillips A, Clements JN. Clinical review of subcutaneous semaglutide for obesity. J Clin Pharm Ther. 2022;47:184–193. doi:10.1111/JCPT.13574
   PubMed Web of Science ®Google Scholar
• Holst JJ, Madsbad S. Semaglutide seems to be more effective the other GLP-1Ras. Ann Transl Med. 2017;5:251–260. doi:10.21037/ATM.2017.11.10
   PubMed Web of Science ®Google Scholar
• Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384:989–1002. doi:10.1056/NEJMOA2032183/SUPPL_FILE/NEJMOA2032183_DATA-SHARING.PDF
   PubMed Web of Science ®Google Scholar
• Hepprich M, Zillig D, Florian-Reynoso MA, Donath MY, Rudofsky G. Switch-to-Semaglutide Study (STS-Study): a retrospective cohort study. Diabetes Ther. 2021;12:943–954. doi:10.1007/S13300-021-01016-Y/FIGURES/3
   PubMed Web of Science ®Google Scholar
• Smits MM, Van Raalte DH. Safety of semaglutide. Front Endocrinol. 2021;12:496. doi:10.3389/FENDO.2021.645563/BIBTEX
   Web of Science ®Google Scholar
• Bacha F. FDA approval of GLP-1 receptor agonist (liraglutide) for use in children. Lancet Child Adolesc Heal. 2019;3:595–597. doi:10.1016/S2352-4642(19)30236-6
   Web of Science ®Google Scholar
• Scott LJ. Liraglutide: a review of its use in the management of obesity. Drugs. 2015;75:899–910. doi:10.1007/S40265-015-0408-8/FIGURES/1
   PubMed Web of Science ®Google Scholar
• Jacobsen LV, Flint A, Olsen AK, Ingwersen SH. Liraglutide in type 2 diabetes mellitus: clinical pharmacokinetics and pharmacodynamics. Clin Pharmacokinet. 2016;55:657–672. doi:10.1007/S40262-015-0343-6/FIGURES/11
   PubMed Web of Science ®Google Scholar
• Sjöholm Å. Liraglutide therapy for type 2 diabetes: overcoming unmet needs. Pharm. 2010;3:764–781. doi:10.3390/PH3030764
   Google Scholar
• Drucker DJ, Dritselis A, Kirkpatrick P. Liraglutide. Nat Rev Drug Discov. 2010;9:267–268. doi:10.1038/NRD3148
   PubMed Web of Science ®Google Scholar
• Montanya E, Sesti G. A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus. Clin Ther. 2009;31:2472–2488. doi:10.1016/j.clinthera.2009.11.034
   PubMed Web of Science ®Google Scholar
• Ponzani P. Long-term effectiveness and safety of liraglutide in clinical practice. Minerva Endocrinol. 2013;38:103–112.
   PubMed Web of Science ®Google Scholar
• Muzurović E, Polyzos SA, Mikhailidis DP, et al. Non-alcoholic fatty liver disease in children. Curr Vasc Pharmacol. 2023;21:4–25. doi:10.2174/1570161121666221118155136
   PubMed Web of Science ®Google Scholar
• Friedrichsen M, Breitschaft A, Tadayon S, Wizert A, Skovgaard D. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabet Obes Metab. 2021;23:754–762. doi:10.1111/DOM.14280
   PubMed Web of Science ®Google Scholar
• Baggio LL, Drucker DJ. Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease. Mol Metab. 2021;46:101090. doi:10.1016/J.MOLMET.2020.101090
   PubMed Web of Science ®Google Scholar
• Paternoster S, Falasca M. Dissecting the physiology and pathophysiology of glucagon-like peptide-1. Front Endocrinol. 2018;2018:584. doi:10.3389/FENDO.2018.00584
   Google Scholar
• Christou GA, Katsiki N, Blundell J, Fruhbeck G, Kiortsis DN. Semaglutide as a promising antiobesity drug. Obes Rev. 2019;20:805–815. doi:10.1111/OBR.12839
   PubMed Web of Science ®Google Scholar
• Carbannel F, Lémann M, Rambaud JC, Mundler O, Jian R. Effect of the energy density of a solid-liquid meal on gastric emptying and satiety. Am J Clin Nutr. 1994;60:307–311. doi:10.1093/AJCN/60.3.307
   PubMed Web of Science ®Google Scholar
• Verdich C, Madsen JL, Toubro S, Buemann B, Holst JJ, Astrup A. Effect of obesity and major weight reduction on gastric emptying. Int J Obes Relat Metab Disord. 2000;24:899–905. doi:10.1038/SJ.IJO.0801250
   PubMed Web of Science ®Google Scholar
• Garaulet M, Gómez-Abellán P, Alburquerque-Béjar JJ, Lee YC, Ordovás JM, Scheer FA. Timing of food intake predicts weight loss effectiveness. Int J Obes. 2013;37:604–611. doi:10.1038/IJO.2012.229
   PubMed Web of Science ®Google Scholar
• Al-Massadi O, Fernø J, Diéguez C, Nogueiras R, Quiñones M. Glucagon control on food intake and energy balance. Int J Mol Sci. 2019;20:3905. doi:10.3390/IJMS20163905
   PubMed Web of Science ®Google Scholar
• Geary N. Glucagon and the control of appetite. In: Glucagon III. Berlin, Heidelberg: Springer Berlin Heidelberg; 1996:223–238.
   Google Scholar
• Maruyama H, Hisatomi A, Orci L, Grodsky GM, Unger RH. Insulin within islets is a physiologic glucagon release inhibitor. J Clin Invest. 1984;74:2296. doi:10.1172/JCI111658
   PubMed Web of Science ®Google Scholar
• Kaneko K, Shirotani T, Araki E, et al. Insulin inhibits glucagon secretion by the activation of PI3-kinase in In-R1-G9 cells. Diabetes Res Clin Pract. 1999;44:83–92. doi:10.1016/S0168-8227(99)00021-2
   PubMed Web of Science ®Google Scholar
• Llewellyn DC, Logan Ellis H, Aylwin SJB, et al. The efficacy of GLP-1RAs for the management of postprandial hypoglycemia following bariatric surgery: a systematic review. Obesity. 2023;31:20–30. doi:10.1002/OBY.23600
   PubMed Web of Science ®Google Scholar
• Sandoval D, Sisley SR. Brain GLP-1 and Insulin Sensitivity. Mol Cell Endocrinol. 2015;418(Pt 1):27. doi:10.1016/J.MCE.2015.02.017
   PubMedGoogle Scholar
• Müller TD, Finan B, Bloom SR, et al. Glucagon-like peptide 1 (GLP-1). Mol Metab. 2019;30:72–130. doi:10.1016/J.MOLMET.2019.09.010
   PubMed Web of Science ®Google Scholar
• Kjems LL, Holst JJ, Vølund A, Madsbad S. The influence of GLP-1 on glucose-stimulated insulin secretion effects on β-cell sensitivity in type 2 and nondiabetic subjects. Diabetes. 2003;52:380–386. doi:10.2337/DIABETES.52.2.380
   PubMed Web of Science ®Google Scholar
• Siamashvili M, Davis SN. Update on the effects of GLP-1 receptor agonists for the treatment of polycystic ovary syndrome. Expert Rev Clin Pharmacol. 2021;14:1081–1089. doi:10.1080/17512433.2021.1933433
   PubMed Web of Science ®Google Scholar
• Bednarz K, Kowalczyk K, Cwynar M, et al. The role of Glp-1 receptor agonists in insulin resistance with concomitant obesity treatment in polycystic ovary syndrome. Int J Mol Sci. 2022;23:4334. doi:10.3390/IJMS23084334
   PubMed Web of Science ®Google Scholar
• Hampl SE, Hassink SG, Skinner AC, et al. Clinical practice guideline for the evaluation and treatment of children and adolescents with obesity. Pediatrics. 2023:151. doi:10.1542/PEDS.2022-060640/190443
   Google Scholar